Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress
📈 **POSITIVE** • Medium confidence analysis (68%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (79%) **Content type:** Clinical